Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
  • A23L2/52—Adding ingredients
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
  • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
  • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
  • A61P39/06—Free radical scavengers or antioxidants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
  • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

• the present invention relates generally to the field of compositions for oral supplementation for energy and cellular enhancement, and methods of modulating a variety of human conditions including, without limitation, psychological and physical energy level, mood, physical performance, weight control, hydration, metabolism, thirst control, blood glucose, and cellular production of free radicals.
• the present invention relates to oral compositions comprising alkyl esters of pyruvic acid, for example without limitation, ethylpyruvate, and to methods of use thereof.
• Ethylpyruvate occurs naturally in a variety of products, including beer.
• the compound is generally recognized as safe by the United State Food and Drug Administration as a synthetic flavoring substance.
• synthetic flavoring substance refers to substances and adjuvants which may be safely used in food in accordance with the following conditions: (a) they are used in the minimum quantity required to produce their intended effect, and otherwise in accordance with all the principles of good manufacturing practice; and (b) they consist of one or more of the compounds listed in 21 C.F.R. ⁇ 172.515, used alone or in combination with flavoring substances and adjuvants generally recognized as safe in food, prior-sanctioned for such use, or regulated by an appropriate section of 21 C.F.R. ⁇ 172.
• U.S. 4,158,057 reports a medical method of preventing excessive accumulation of fatty deposits in the liver of a mammal due to ingestion of ethanol, which method includes administering orally to the mammal a mixture of pyruvate and dihydroxyacetone, optionally riboflavin.
• U.S. 5,294,641 reports a medical method for increasing the cardiac output of a human without concurrently increasing the cardiac oxygen demand of the human which comprises includes feeding the human, orally or intravenously, pyruvate, optionally as an organic ester.
• U.S. 5,480,909 reports a medical method for inhibiting free-radical generation and concurrently scavenging internally generated-free radicals in a mammal by administering to the mammal pyruvate, or a pharmaceutically acceptable ester thereof.
• U.S . 5,801 , 198 reports a medical method for retarding loss of morphology in the bowel of a mammal experiencing ischemic bowel by introducing pyruvate, or organic ester thereof, enterally or parenterally into the mammal prior to and during the ischemic bowel or during reperfusion.
• U.S. 6,846,842 describes a medical method for treating a mammal suffering from ischemia or reperfusion injury by administering an ester of a 2 ketoalkanoic acid selected from the group consisting of ethyl pyruvate, propyl pyruvate, butyl pyruvate, carboxymethyl pyruvate, acetoxymethyl pyruvate, carbethoxymethyl pyruvate and ethoxymethyl pyruvate in a pharmaceutically-acceptable carrier, wherein the carrier further comprises an organic or inorganic cation.
• a 2 ketoalkanoic acid selected from the group consisting of ethyl pyruvate, propyl pyruvate, butyl pyruvate, carboxymethyl pyruvate, acetoxymethyl pyruvate, carbethoxymethyl pyruvate and ethoxymethyl pyruvate in a pharmaceutically-acceptable carrier, wherein the carrier further comprises
• the invention provides a composition for ingestion which is a food, dietary supplement or pharmaceutical, which composition comprises pyruvic acid alkyl ester, wherein the pyruvic acid alkyl ester is present at greater than 0.01 weight-percent.
• the composition for ingestion is a food or dietary supplement rather than a pharmaceutical.
• the pyruvic acid alkyl ester is ethylpyruvate.
• pyruvate esters are sufficiently lipophilic to be taken up by cells at a faster rate than equimolar amounts of pyruvic acid per se or any tautomeric or charged forms thereof. Accordingly, pyruvate esters in the compositions of the present invention serve as carriers for intracellular pyruvate delivery made bioavailable after non-specific ester solvolysis by ubiquitous cytosolic carboxyesterases.
• Pyruvate oxidation connects glycolysis to the tricarboxylic acid cycle whereby pyruvate molecules formed during glycolysis are transported from the cytoplasm through the mitochondrial membranes into the mitochondrial matrix, wherein the pyruvate dehydrogenase complex catalyzes known biochemical reactions which result in the production of acetyl-Co A. Accordingly, direct provision of pyruvic acid circumvents the need for production of pyruvic acid via glycolysis for cellular energy.
• “Ingestion” refers in the context of compositions and methods of the present invention to the taking of a composition into the body via the alimentary canal.
• Dietary supplement refers to a product as defined under the United States Dietary Supplement Health and Education Act of 1994, which product is intended to supplement the diet and bears or contains one or more of a vitamin, a mineral; an herb or other botanical (excluding tobacco), an amino acid, a dietary substance for use by man to supplement the diet by increasing the total dietary intake, or a concentrate, metabolite, constituent, extract or combination of any of these components.
• a dietary supplement is intended for ingestion in pill, capsule, tablet, powder or liquid form, and is not represented for use as a conventional food or as the sole item of a meal or diet labeled as a "dietary supplement.”
• the terms “oral supplement” and “dietary supplement” are.used interchangeably herein.
• “Pyruvic acid alkyl ester/' "alkyl ester of pyruvic acid” and like terms refer to compounds of Formula I, and all tautomeric and charged forms thereof,
• R 1 is alkyl.
• compounds of Formula I can undergo enolization to form enols of Formula II, which enols can deprotonate to compounds of Formula III. Accordingly, such tautomeric and charged forms are contemplated by the term alkyl ester of pyruvic acid.
• pyruvic acid the terms “pyruvic acid,” “pyruvate” and like chemical terms are used interchangeably, all referring to the various tautomeric and charge states of pyruvic acid.
• alkyl refers to straight, branched chain, or cyclic hydrocarbyl groups including from 1 to about 20 carbon atoms.
• Alkyl includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, and the like, and also includes branched chain isomers of straight chain alkyl groups, for example without limitation, -CH(CH 3 ) 2 , -CH(CH 3 )(CH 2 CH 3 ), -CH(CH 2 CHs) 2 , -C(CHa) 3 , -C(CH 2 CH 3 ) 3 , -CH 2 CH(CHa) 2 , -CH 2 CH(CH 3 )(CH 2 CH 3 ), -CH 2 CH(CH 2 CHs) 2 , -CH 2 C(CH 3 )J
• alkyl groups include primary alkyl groups, secondary alkyl groups, and tertiary alkyl groups.
• Preferred alkyl groups include alkyl groups having from 1 to 6 carbon atoms, more preferred alkyl groups have 2 carbon atoms (i.e., ethylpyruvate). It is understood that all compositions and methods provided by the present invention which comprise pyruvic acid alkyl esters include any of the alkyl esters specified above and most preferably ethylpyruvate.
• Weight-percent refers to the ratio of the mass of a specified component of a composition to the total mass of the composition, expressed as a percentage. Accordingly, 0.1 weight-percent is equivalent to 1.0 gm/kg (i.e., 1000 parts per million), 0.01 weight-percent is equivalent to 0.1 gm/kg (i.e., 100 parts per million), and so forth.
• “Pharmaceutical” and like terms refer to compounds, for example drugs, which have been found effective to treat and/or ameliorate one or more specific diseases for which the compound is approved, and which meet safety criteria, well known to those of skill in the art, by being subject to extensive animal and/or controlled human testing. Pharmaceuticals are typically administered in accordance with a medical method under the direction of trained medical personnel.
• Medical method and like terms refer to a method of treatment conducted under the auspices of a trained medical practitioner.
• Compounds and compositions employed in medical methods are pharmaceuticals as defined herein.
• the pyruvic acid alkyl ester used in the compositions of the invention is preferably ethylpyruvate.
• ethylpyruvate contemplates all tautomeric and charged forms of the compound according to any of Formulae I-III having R 1 equal to ethyl.
• the nutritional content afforded by ethylpyruvate as an oral supplement accounts for 0.1-50% of the daily nutritional needs of the subject. In some embodiments, the nutritional content afforded is within another range, e.g., 0.1- 40%, 0.1-30%, 0.1-20%, 0.1-10%, 0.1-5%, 0.1-1%.
• the invention provides methods for the energy enhancement of a human upon ingesting an effective amount of a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• Energy enhancement refers to a subjective feeling by a human subject that the strength, stamina and/or inclination to undertake a task has been increased by ingestion of a composition of the invention.
• An energy enhancement may be accompanied by feelings that additional need for energy is not required.
• energy enhancement may accompany a feeling by a human subject that additional stimulation e.g., ingesting a caffeine containing food or beverage, is not necessary in the contemplation of a task.
• additional stimulation e.g., ingesting a caffeine containing food or beverage
• an effective amount of a composition according to the present invention may contemplate a variety of ranges of amount of pyruvic acid alkyl ester, depending on the human subject, including for example without limitation, 100 mg to 100 gm, 100 mg to 200 gm, 100 mg to 500 gm, and specific amounts therein, e.g.: about 100 mg, 200 mg, 500 mg, 1 gm, 2, gm, 3 gm, 4 gm, 5 gm, 10 gm, 15 gm, 20 gm, 30 gm, 40 gm, 50 gm, 100 gm, 200 gm, 300 gm, 400 gm or even 500 gm. These amounts can be delivered by multiple administrations over a period of time.
• compositions and composition indicate that the specified composition does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the composition to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration.
• the invention provides methods for the enhancement of physical performance by a human upon ingesting an effective amount of a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• Physical performance refers to objective indicia of physical activity, as well known in the art, and to a subjective feeling or belief by a human subject that greater physical ability attends the ingestion of a composition according to the present invention.
• the invention provides a method for promoting weight loss in a human, which method comprising ingesting an effective amount of a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• Benefits of the invention may be afforded by oral ingestion of the pyruvic acid alkyl ester to account for a specific percentage of daily nutritional need, as well known in the art, for example without limitation, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or even higher.
• the invention provides a method for mood enhancement in a human, the method comprising oral ingestion of a compound of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• “Mood” and like terms in the context of human feelings refer to a subjective self-assessment of a human, for example without limitation, feelings of being tired, normal, energetic, excited, and the like, all readily understood.
• “mood enhancement” and like terms refer to an improvement (e.g., more elevated, typically happier or more satisfied) in mood following ingestion of the composition.
• the invention provides a method for enhancement of physical performance in a human, the method comprising oral ingestion of a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• "Enhancement of physical performance” refers to both an objective increase in, for example and without limitation, strength and stamina of a human, as judged by physiological methods well known in the art, and additional to a subjective increase in feelings of well-being and potential to undertake a physical task.
• the invention provides a method for re-hydration or thirst quenching of a human, the method comprising oral ingestion of an aqueous (e.g., beverage) composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• an aqueous (e.g., beverage) composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• the invention provides a method for metabolism enhancement in a human, the method comprising oral ingestion of a composition of the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• provision of pyruvic acid resulting from ester hydrolysis of an alkyl ester thereof (e.g., ethylpyruvate) provided by a composition of the invention facilitates the increase in flux through the tricarboxylic acid cycle, thereby providing for enhancement of metabolism.
• the invention provides a method for supplementing, via an oral supplement, the actions of intravenous infusion of ethylpyruvate for resuscitation of cardiac, muscle or nerve tissue, the method comprising oral ingestion of a composition according to the present invention.
• the invention provides a method for increasing fat metabolism, and thereby decreasing depot fat, in a human, the method comprising oral ingestion of an effective amount of a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• the invention provides a method for decreasing blood glucose levels in a human, the method comprising oral ingestion of an effective amount of a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate. Accordingly, reduction in blood glucose may be afforded by oral ingestion of an alkyl ester of pyruvic acid to account for a specific percentage of daily nutritional need, as well known in the art, for example without limitation, 0.1%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or even higher.
• the invention provides a method for inhibition of the cellular production of free radicals in a human, the method comprising oral ingestion of an effective amount of a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate. Accordingly, reduction in cellular production of free radicals may be afforded by oral ingestion of an alkyl ester of pyruvic acid to account for a specific percentage of daily nutritional need, as well known in the art, for example without limitation, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50% or even higher.
• pyruvic acid per se has anti-oxidant properties, for example, pyruvate has been reported as a free radical scavenger (see, e.g., De Boer, L. W. V. et al, Am. J. Physiol 265 (Heart Circ. Physiol 341): H1571-H11576, 1993).
• the invention provides a method for improvement of cognitive, language, behavior or social skills of an autistic human, the method comprising oral ingestion of an effective amount of a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• the invention provides a method for enhancing the recovery of a human from a disease, the disease selected from the group consisting of mononucleosis, chronic fatigue syndrome, and viral infection, the method comprising repeated oral ingestion of an effective amount of a composition according to the invention comprising a pyruvic acid alkyl ester as defined herein.
• the pyruvic acid alkyl ester is ethylpyruvate.
• the invention provides a food additive comprising greater than 0.01 weight-percent alkyl ester of pyruvic acid. In some embodiments, the food additive comprises greater than 0.01 weight-percent ethylpyruvate.
• the amount of pyruvic acid alkyl ester (e.g., ethylpyruvate) is present in the range greater than 0.01 to 30 weight-percent. In other embodiments, the range is greater than 0.01 to about 30 weight-percent. "About" in the context of numeric values and ranges indicates the nominal value +/- 10%.
• the amount of pyruvic acid alkyl ester (e.g., ethylpyruvate) is present in the following approximate ranges (i.e., +/- 10%): 0.02-0.05, 0.05-0.1, 0.1-1, 1-2, 2-5, 5-10, 10-20, or 20-30 weight-percent. In certain embodiments, the amount of pyruvic acid alkyl ester (e.g., ethylpyruvate) is present in specific amounts, e.g., about 0.02, 0.05, 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 or even 30 weight-percent.
• the present invention provides compositions for oral ingestion comprising pyruvic acid alkyl ester, and in particular ethylpyruvate, wherein the composition lacks sodium or calcium. In certain embodiments, the present invention provides compositions for oral ingestion comprising pyruvic acid alkyl ester, and in particular ethylpyruvate, wherein the composition further comprises sodium, calcium, and/or magnesium.
• the present invention provides compositions for oral ingestion comprising pyruvic acid alkyl ester, and in particular ethylpyruvate, wherein the compositions are in the form of food.
• a "food” is a nutritious solid, semi-solid, liquid, food ingredient or food additive.
• "Semi-liquid” refers in the context of food to an otherwise solid component dispersed in a liquid milieu, e.g. without limitation, cereal in milk.
• a food bar or candy bar comprising a pyruvic acid alkyl ester as defined herein (e.g. ethylpyruvate) is an exemplary solid food composition of the invention.
• the compositions provided by the invention are foods or dietary supplements in the form of a beverage. In certain embodiments, the compositions are foods. In certain embodiments, the compositions are dietary supplements.
• a liquid or beverage composition for oral ingestion can be taken cold (e.g., with ice), at room temperature, or after heating to a convenient temperature (e.g., 80- 120 degrees F) depending on the needs of the human.
• a convenient temperature e.g. 80- 120 degrees F
• the present invention provides a food additive or food ingredient comprising a pyruvate alkyl ester.
• Food additive or “food ingredient” refers to substances which are not typically ingested per se, but which are used in the preparation of food and/or beverages to achieve the benefits provided by the compositions of the invention.
• Examples of food additive or ingredient include, without limitation, a concentrated form of a composition according to the present invention for mixing with a beverage or food component during preparation thereof.
• compositions provided by the present invention further comprise one or more components selected from the group consisting of flavorings, colorings, non-carbohydrate sweeteners, vitamins, electrolytes, Coenzyme Qio, aloe, minerals, fulvic acid, mushrooms, dissolved effervescent gas, amino acids, carbohydrates, stimulants, proteins, herbs, essential oils and extracts.
• a single ingestion of a composition provided herein is sufficient to elicit a beneficial response.
• increase in physical performance, enhancement of mood, re-hydration, thirst quenching, metabolic enhancement, enhancement of fat metabolism, decrease in blood glucose, and inhibition of cellular production of radical chemical species can be observed upon ingestion of a single portion of a composition of the invention.
• the single portion provides the nutritional content equivalent to 0.1-50% of the daily nutritional needs of the subject.
• the nutritional content afforded is within another range, e.g., 0.1-40%, 0.1-30%, 0.1-20%, 0.1-10%, 0.1-5%.
• a single portion of a composition of the invention is generally a volume of fluid or solid than can be ingested in one sitting, which sitting may last from less than a minute to several minutes and generally up to less than an hour.
• Exemplary single portions can include 1-4 oz solid bar or an 8-32 oz drink.
• repeated ingestion of a composition provided herein facilitates a beneficial response.
• promotion of weight loss supplementation of the action of intravenous infusion of pharmaceuticals (e.g., ethylpyruvate or other alkyl ester of pyruvic acid delivered via a non-oral mode), increased fat metabolism, and enhanced recovery from a disease selected from the group consisting of mononucleosis, chronic fatigue syndrome, and viral infection, can be observed upon repeated ingestion of portions of a composition of the invention over an extended period of time (e.g., days to weeks).
• the portions contemplated for repeated ingestion provide nutritional content equivalent to 0.1-50% of the daily nutritional needs of the subject.
• the nutritional content afforded is within another range, e.g., 0.1-40%, 0.1-30%, 0.1-20%, 0.1-10%, 0.1-5%.
• ethylpyruvate in solution demonstrates higher stability at room temperature (e.g., about 50 to 90 degrees F) than does the methyl ester of pyruvic acid, or corresponding tautomeric and/or charged forms thereof, as judged by appearance (e.g., color) and taste.
• room temperature e.g., about 50 to 90 degrees F
• methyl esters of pyruvic acid are more susceptible to hydrolysis in aqueous solution than are corresponding ethyl esters, which hydrolysis results in the production of pyruvic acid.
• Pyruvic acid, and the anion thereof can then react by mechanisms well known in the art, to form a plethora of higher molecular compounds. Accordingly, the higher stability of ethylpyruvate results in longer shelf life for compositions of the present invention, as compared with corresponding compositions employing the methyl ester of pyruvic acid.
• the panel was additionally provided a corresponding liquid composition of rnethylpyruvate (i.e., methyl ester of pyruvic acid) for comparative tasting.
• rnethylpyruvate i.e., methyl ester of pyruvic acid
• compositions of the present invention could include a carbonated beverage comprising a pyruvate alkyl ester (e.g., ethylpyruvate), optionally added vitamins and minerals, to provide a refreshing alternative to soft drinks.
• a carbonated beverage comprising a pyruvate alkyl ester (e.g., ethylpyruvate), optionally added vitamins and minerals, to provide a refreshing alternative to soft drinks.
• exemplary vitamin and mineral components include vitamins B3, B6, Bl 2; exemplary minerals include zinc, sodium, magnesium, and calcium.
• compositions could include candy bars or energy bars comprising a pyruvate alkyl ester (e.g., ethylpyruvate).
• a pyruvate alkyl ester e.g., ethylpyruvate
• Methods of manufacture of candy bars are well known in the art (see e.g., U.S. 4,491,597).
• the pyruvate alkyl ester e.g., ethylpyruvate
• compositions could include suspensions or solutions of a pyruvate alkyl ester (e.g., ethylpyruvate) in combination with shaved, granulated, crushed, or pulverized ice to afford, for example without limitation, "snow cones” or “slush” drinks comprising ethylpyruvate.
• a pyruvate alkyl ester e.g., ethylpyruvate
• shaved, granulated, crushed, or pulverized ice to afford, for example without limitation, "snow cones” or “slush” drinks comprising ethylpyruvate.
• snow cones are made by depositing flaked ice into a cone shaped cup and applying a flavoring syrup thereon (see U.S. 4,174,742).
• slush drinks comprise ice and flavorings and are typically dispensed at the point of sale with specialized machinery, well known in the art.
• compositions could include chewing gums or soups to which pyruvate alkyl ester (e.g., ethylpyruvate) has been added.
• pyruvate alkyl ester e.g., ethylpyruvate
• Each subject additionally reported better performance in high-activity training regimens (e.g., "wind sprints" as known in the art) relative to performance reported in practice sessions prior to oral ingestion of ethylpyruvate.
• any of the terms “comprising”, “consisting essentially of and “consisting of may be replaced with either of the other two terms.
• the invention also includes another embodiment wherein one of these terms is replaced with another of these terms.
• the terms have their established meaning.
• one embodiment may encompass a method “comprising” a series of steps, another embodiment would encompass a method “consisting essentially of the same steps, and a third embodiment would encompass a method "consisting of the same steps.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Nutrition Science (AREA)
• Emergency Medicine (AREA)
• Epidemiology (AREA)
• Polymers & Plastics (AREA)
• Food Science & Technology (AREA)
• Neurology (AREA)
• Mycology (AREA)
• Endocrinology (AREA)
• Cardiology (AREA)
• Toxicology (AREA)
• Biomedical Technology (AREA)
• Communicable Diseases (AREA)
• Neurosurgery (AREA)
• Child & Adolescent Psychology (AREA)
• Heart & Thoracic Surgery (AREA)
• Oncology (AREA)
• Biochemistry (AREA)
• Virology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=38610076

Family Applications (1)

Country Status (8)

Cited By (1)

Families Citing this family (1)

Citations (17)

Family Cites Families (22)

• 2007
  • 2007-04-04 US US12/296,527 patent/US20100047221A1/en not_active Abandoned
  • 2007-04-04 NZ NZ572649A patent/NZ572649A/en not_active IP Right Cessation
  • 2007-04-04 AU AU2007238938A patent/AU2007238938B2/en not_active Ceased
  • 2007-04-04 EP EP07754798.2A patent/EP2010218B1/en not_active Not-in-force
  • 2007-04-04 JP JP2009505389A patent/JP2009533433A/ja active Pending
  • 2007-04-04 CN CNA2007800216659A patent/CN101472613A/zh active Pending
  • 2007-04-04 WO PCT/US2007/008334 patent/WO2007120544A2/en not_active Ceased
  • 2007-04-04 CA CA2683664A patent/CA2683664C/en not_active Expired - Fee Related
• 2015
  • 2015-02-18 US US14/624,854 patent/US20150157589A1/en not_active Abandoned

Patent Citations (17)

Also Published As

Similar Documents

Legal Events